高度進行肝細胞癌に対するシスプラチン動注化学療法 : 重篤な有害事象は稀ではない

概要

論文の詳細を見る
The aim of this study was to clarify the frequency of severe toxicity in hepatic arterial cisplatin infusion chemotherapy for far advanced hepatocellular carcinoma patients. Study subjects were consecutive 18 patients with hepatocellular carcinoma no longer amenable to transcatheter arterial chemoembolization. Hepatic arterial infusion using cisplatin 100 mg alone was repeated at 4 to 6-week intervals until disease progression. According to National Cancer Institute Common Toxicity Criteria version 2, the grade 3 or worse hematological and non-hematological adverse events (reactions) were observed in 7 (6) and 14 (12) of the 18 patients, respectively. Two patients died within 2 months due to possible toxicities of the treatment. This treatment was so toxic that candidates should be selected among patients with good hepatic reserve.
社団法人　日本肝臓学会の論文
2005-04-25